top of page
Multiple Myeloma Clinical Trials - Canada
NCT04973605
NCT05372354
NCT02343042
NCT04973605
1/46
Multiple Myeloma Clinical Trials
2022 - NCT05572515
Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
2022 - NCT05556616
Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
2022 - NCT05552222
Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
2022 - NCT05519085
Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
2022 - NCT05461209
Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)
2022 - NCT05372354
Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
2022 - NCT05317416
Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
2021 - NCT05090566
Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
2021 - NCT05083169
Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
2021 - NCT05064358
Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)
2021 - NCT05020236
Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
2021 - NCT04975997
Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
2021 - NCT04975399
Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
2021 - NCT04973605
Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
2021 - NCT04923893
Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
2021 - NCT04910568
Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
2021 - NCT04786028
Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
2021 - NCT04721002
Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
2021 - NCT03901963
Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
2020 - NCT04586426
Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
2020 - NCT04557098
Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
2020 - NCT04484623
Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
2020 - NCT04270409
Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
2020 - NCT04268199
Phase 2: Exploring Self-Administration of Chemo in the Home Environment (EASE)
2020 - NCT04258683
Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE
bottom of page